Reply to: Skin moisturization for xerosis related to targeted anticancer therapies

To the Editor: We would like to thank Drs Gisondi and Girolomoni for their comments regarding the treatment of xerosis. We agree that salicylic acid and ammonium lactate should be used judiciously, and only on areas of hyperkeratosis without evident dermatitis, as is commonly seen in patients treated with targeted therapies. Indeed, targeted therapies lead to aberrant keratinocyte proliferation, migration, differentiation, and adhesion, all of which result in xerotic skin with retention hyperkeratosis.1 Patients receiving targeted therapies who develop xerosis and hyperkeratosis require rapid resolution of findings, because progression into a grade 3 adverse event dictates interruption, dose decrease, or discontinuation of life-prolonging anticancer treatments. Therefore, according to the treatment algorithm in Fig 4 of our manuscript, salicylic acid or ammonium lactate is to be used in conjunction with emollients and topical steroids to eczematous areas.2 These treatment recommendations are based on clinical experience at a dermatology referral clinic for patients on targeted therapies started in 2006.3

• Fecha de publicación: 2015
• Institución: Universidad del Rosario
• Repositorio: Repositorio EdocUR - U. Rosario
• Idioma: eng
• OAI Identifier: oai:repository.urosario.edu.co:10336/25970
• Acceso en línea: https://doi.org/10.1016/j.jaad.2015.03.038; https://repository.urosario.edu.co/handle/10336/25970
• Palabra clave: Antineoplastic agent; Antineoplastic agent; Enzyme inhibitor; Monoclonal antibody; Eczema; Human; Hyperkeratosis; Incidence; Keratinocyte; Letter; Moisture; Molecularly targeted therapy; Priority journal; Skin function; Skin moisturization; Xerosis; Adverse effects; Chemically induced; Molecularly targeted therapy; Neoplasms; Skin disease; Antibodies; monoclonal; Antibodies; monoclonal; Antineoplastic agents; Antineoplastic agents; Enzyme inhibitors; Enzyme inhibitors; Humans; Humans; Molecular targeted therapy; Molecular targeted therapy; Neoplasms; Neoplasms; Skin diseases; Skin diseases
• License: Restringido (Acceso a grupos específicos)